

Corp. Off.: 502, Kanakia Atrium - 2,  
Next to Courtyard Marriott Hotel,  
Andheri Kurla Road, Andheri (East),  
Mumbai - 400 093 (India)  
Ph.: + 91 22 61933100 Fax : +91 22 61933114

14<sup>th</sup> November, 2018

**BSE Limited**

Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai-400001

**National Stock Exchange of India Ltd.**

Exchange Plaza, C-1, Block G  
Bandra Kurla Complex  
Bandra (E), Mumbai-400051

**Kind Attn: General Manager-DCS**

Scrip Code: 533543

**Kind Attn: Head- Listing**

Symbol: **BROOKS**

**Sub: Disclosure under Regulation 30 & Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015**

Dear Sirs,

This has in reference to the regulation mentioned above:


We hereby inform you that the Board of Directors at its meeting held today has, inter alia, approved the Unaudited Financial Results of the Company for the 2<sup>nd</sup> quarter and half yearly ended 30<sup>th</sup> September, 2018. The Audit Committee reviewed the Unaudited Financial Results at its meeting held earlier today which have been subjected to a limited review by the Statutory Auditors. The Statement of Unaudited Financial Results, Statement of Assets and Liabilities as at 30.09.2018 together with the Limited Review Report is attached.


This is for your information and record.

Thanking You,

Yours faithfully

For **BROOKS LABORATORIES LIMITED**

  
(Jyoti Sancheti)



**Company Secretary cum Compliance Officer**

**Membership No. F9639**

Encl.: As Stated Above

**Brooks Laboratories Limited**

Regd Office: Village Kishanpura, Nalagarh Road, Baddi, Dist. Solan H.P.-174101

CIN NO: L24232HP2002PLC000267

E-mail : investors@brookslabs.net

Website: www.brookslabs.net

Tel No : +91 1795 654001/02/03,

Fax No : +91 1795 236939

**Statement of Unaudited Financial Results for the Quarter / Half Year ended 30<sup>th</sup> September, 2018**

(Rs. In Lakhs)

No	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30-Sep-18	30-Jun-18	30-Sep-17	30-Sep-18	30-Sep-17	31.03.2018
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
<b>1</b>	<b>Income</b>						
	(a) Revenue from operations	1,410.34	1,067.33	1,316.51	2,477.67	2,151.31	5,690.42
	(b) Other Income	5.32	26.46	6.42	31.78	9.90	24.02
	<b>Total Income</b>	<b>1,415.66</b>	<b>1,093.79</b>	<b>1,322.93</b>	<b>2,509.45</b>	<b>2,161.21</b>	<b>5,714.44</b>
<b>2</b>	<b>Expenses</b>						
	(a) Cost of materials consumed	980.08	781.64	917.35	1,761.71	1,510.86	4,084.63
	(b) Change In Inventories of finished goods, work In progress and stock-in-trade	(13.48)	70.00	62.89	56.52	(35.64)	(147.03)
	(c) Excise Duty on Sales	-	-	-	-	119.27	119.27
	(d) Employees benefits expenses	286.66	270.41	288.96	557.06	543.91	1,180.73
	(e) Finance Costs	77.55	69.52	54.69	147.07	100.22	244.02
	(f) Depreciation and amortization expenses	157.01	162.93	162.05	319.94	318.81	644.51
	(g) Other expenses	306.20	301.27	317.83	607.49	627.94	1,341.73
	<b>Total Expenses</b>	<b>1,794.02</b>	<b>1,655.77</b>	<b>1,803.77</b>	<b>3,449.79</b>	<b>3,185.37</b>	<b>7,467.86</b>
<b>3</b>	<b>Profit/(Loss) before exceptional items and tax</b>	<b>(378.38)</b>	<b>(561.98)</b>	<b>(480.84)</b>	<b>(940.36)</b>	<b>(1,024.16)</b>	<b>(1,753.42)</b>
<b>4</b>	<b>Exceptional Items</b>	-	-	-	-	-	-
<b>5</b>	<b>Profit/(Loss) from ordinary activities before tax</b>	<b>(378.38)</b>	<b>(561.98)</b>	<b>(480.84)</b>	<b>(940.36)</b>	<b>(1,024.16)</b>	<b>(1,753.42)</b>
<b>6</b>	<b>Tax Expense:</b>						
	Current Tax	-	-	-	-	-	-
	Deferred Tax Liability / (Assets)	(178.29)	(190.59)	(178.67)	(368.88)	(134.31)	(375.09)
	Short income tax provision for earlier years	-	-	-	-	2.95	2.95
<b>7</b>	<b>Net Profit/(loss) after tax</b>	<b>(200.09)</b>	<b>(371.39)</b>	<b>(302.17)</b>	<b>(571.48)</b>	<b>(892.80)</b>	<b>(1,381.28)</b>
<b>8</b>	<b>Other Comprehensive Income Items That will not be reclassified into Profit or loss</b>						
	Actuarial loss on Defined Benefit plans (net of tax).	0.20	0.20	0.01	0.41	0.02	0.81
<b>9</b>	<b>Total Comprehensive Income for the period (After tax)</b>	<b>(199.89)</b>	<b>(371.19)</b>	<b>(302.16)</b>	<b>(571.07)</b>	<b>(892.78)</b>	<b>(1,380.47)</b>
<b>10</b>	<b>Paid - up equity share capital of Rs.10 each</b>	1,618.64	1,618.64	1,618.64	1,618.64	1,618.64	1,618.64
<b>11</b>	<b>Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year</b>	11,209.05	11,209.05	11,227.83	11,209.05	11,227.83	11,209.05
<b>12</b>	<b>Earnings per share of Rs.10/- each (not annualised):</b>						
	(a) Basic	(1.24)	(0.83)	(1.87)	(3.53)	(5.52)	(8.53)
	(b) Diluted	(1.24)	(0.83)	(1.87)	(3.53)	(5.52)	(8.53)

**For Brooks Laboratories Ltd.**

  
**Chairman**

**Notes:**


- 1 The above unaudited financial results of the Company for the quarter/ half year ended 30th September, 2018 have been reviewed and recommended by the Audit Committee and approved and taken on record by the Board of Directors in their respective meetings held on 14th November, 2018
- 2 The financial results have been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- 3 The Statutory Auditors have carried out Limited Review of the Financial Results and of the Company for the Quarter/Half Year ended September 30, 2018.
- 4 Consequent to the introduction of Goods and Services Tax (GST) with effect from July 1, 2017, Central Excise Duty, Value Added Tax (VAT), etc, have been replaced by GST. In accordance with Ind AS-18 "Revenue" and Schedule-III of Companies Act, 2013, GST is not included in total income from operation for quarter ended September 30th, 2017. However, for the quarter ended June 30th, 2017 and earlier comparative periods, excise duty is included in revenue from operations hence not comparable.
- 5 The Company is mainly engaged in the business of "Pharmaceutical Formulations" and there is no other reportable business segment. As the Company's business actually falls within a single primary business segment, the disclosure requirements of Ind-AS - 108 in this regard are not applicable.
- 6 In terms of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2009 as amended ("ICDR Regulations"), the company upon the shareholders approval at the Annual General Meeting held on 10th August, 2018 issued and allotted 8,50,000 Share warrants, by circular resolution dated 6th September, 2018 and 14th September, 2018 at a conversion price of Rs. 95.50 per Equity share aggregating to Rs 8,11,75,000 of which Rs 2,61,49,000/- was received by the company from the allottee's as upfront amount. These warrants will be converted into an equivalent number of Equity shares of face value Rs. 10 each at premium of Rs 85.50 per share, in the company, upon receipt of balance conversion price, within a period of 18 months from the date of allotment.
- 7 Comparative financial information of the previous quarter and half yearly have been regrouped and reclassified, wherever necessary, to correspond to the figures of the current period presentation.

Place : Mumbai

Date : 14th November, 2018

For and on Behalf of Board

  
Chairman  
DIN No. 01998361




Brooks Laboratories Limited  
Statement of Assets & Liabilities as at September 30, 2018

(Rs. In Lakhs)

Particulars	As at September 30, 2018	As at March 31, 2018
	Unaudited	Audited
<b>A ASSETS</b>		
<b>1 Non Current Assets</b>		
(a) Property, Plant and Equipment	11,969.91	12,401.04
(b) Capital work-in-progress	59.16	52.16
(c) Investment Property	63.35	63.35
(c) Financial assets		
(i) Investments	2.00	2.00
(ii) Other Financial Assets	93.41	140.63
(d) Other Non Current Assets	3.36	129.57
(e) Income Tax Asset (Net)	440.97	438.92
(f) Deferred tax Asset (Net)	1,445.59	1,073.97
<b>Total Non - Current Assets</b>	<b>14,077.75</b>	<b>14,301.64</b>
<b>2 Current assets</b>		
(a) Inventories	1,017.94	1,140.91
(b) Financial Assets		
(i) Trade receivables	1,096.23	1,018.24
(ii) Cash and Cash Equivalents	21.76	64.55
(iii) Bank Balances other than Cash & cash equivalents	117.83	131.95
(iv) Loans	29.11	120
(iv) Other Financial Assets	37.54	32.22
(c) Other Current Assets	524.11	575.75
<b>Total Current Assets</b>	<b>2,844.52</b>	<b>2,964.82</b>
<b>TOTAL ASSETS</b>	<b>16,922.27</b>	<b>17,266.46</b>
<b>B EQUITY AND LIABILITIES</b>		
<b>1 Equity</b>		
(a) Equity Share Capital	1,618.64	1,618.64
(b) Other Equity (Refer Note No.6)	9,519.00	9,828.59
<b>Total Equity</b>	<b>11,137.64</b>	<b>11,447.23</b>
<b>Liabilities</b>		
<b>2 Non-current liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	1,583.19	1,725.84
(b) Provisions	131.59	108.42
<b>Total Non - Current Liabilities</b>	<b>1,714.78</b>	<b>1,834.26</b>
<b>3 Current liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	946.35	854.44
(ii) Trade Payables	-	-
- Due to micro and small enterprises	12.60	76.68
- Due to Others	2,689.93	2,572.87
(iii) Other Financial Liabilities	362.81	353.98
(b) Other current liabilities	58.16	92.49
(c) Provisions	-	34.51
<b>Total Current Liabilities</b>	<b>4,069.85</b>	<b>3,984.97</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>16,922.27</b>	<b>17,266.46</b>

Place: Mumbai  
Date : 14th November, 2018



For Brooks Laboratories Limited

Chairman  
DIN No. 01998361

# **SGCO & Co. LLP**

Chartered Accountants

Limited Review Report on the Unaudited Financial Results of Brooks Laboratories Limited For the quarter and half year ended September 30, 2018 Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To  
The Board of Directors  
Brooks Laboratories Limited

1. We have reviewed the accompanying Statement of Unaudited Financial Results of Brooks Laboratories Limited ("the Company") for the quarter and half year ended 30<sup>th</sup> September 2018 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement which is the responsibility of the Company's Management and have been approved by the Board of Directors in their meeting held on 14<sup>th</sup> November, 2018, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" as prescribed under section 133 of Companies Act, 2013 ("the Act") read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.

2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

4A, Kaledonia-HDIL,  
2<sup>nd</sup> Floor, Sahar Road,  
Near Andheri Station,  
Andheri (East),  
Mumbai - 400 069. India

Tel.: +91 22 6625 6363  
Fax: +91 22 6625 6364  
E-mail: info@sgco.co.in  
www.sgco.co.in




Mumbai ● Bengaluru

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respect in accordance with Ind AS and other recognized accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 read with Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For S G C O & Co. LLP**

Chartered Accountants

**Firm's Registration No. 112081W/W100184**

  
**Suresh Murarka**

Partner

**Mem. No. 044739**



Place : Mumbai

Date: 14<sup>th</sup> November, 2018